Opinion|Podcasts|October 25, 2024
Impact of CSU on Patient Quality of Life
Key Takeaways
- CSU significantly affects patients' clinical and psychosocial well-being, leading to increased depression and sleep disturbances.
- The chronic nature of CSU results in frequent absenteeism and negatively impacts professional life, reducing productivity.
Panelists discuss how chronic spontaneous urticaria (CSU) significantly impacts patients’ overall well-being, both clinically and psychosocially, highlighting increased prevalence of depression, sleep disturbances, absenteeism, and adverse effects on professional life.
Advertisement
Episodes in this series
Video content above is prompted by the following:
- How does CSU affect a patient’s overall well-being (clinical and psychosocial)?
Can you share insights on the increased prevalence of depression, sleep, absenteeism, impact on professional life, etc, in patients with CSU?
Advertisement
Related to this article
Katherine Tuttle, MD, joins Brendon Neuen, MBBS, PhD, and Shikha Wadhwani, MD, MS, to unpack new FIND-CKD finerenone analyses from ASN 2026.
Jicheng Lv, MD, joins Brendon Neuen, MBBS, PhD, and Shikha Wadhwani, MD, MS, to discuss 2-year TELIGAN data for telitacicept in IgAN.
A PROTECT biomarker analysis shows sparsentan reduced urinary sCD163, BAFF, C5b-9, and IL-6 vs irbesartan through 110 weeks in IgA nephropathy.
Diana Isaacs, PharmD, and Natalie Bellini, DNP, review early MiniMed Vivera data on optional meal announcements and twiist's new type 2 diabetes clearance.
Real-world data in 1477 patients on dialysis show tenapanor reduced serum phosphate at 6 months with or without background phosphate binders.
Approval rests on the phase 3 AFFIRM trial, in which 56% of patients reached clinical remission at week 12 vs 30% with placebo.
Jean Elwing, MD, discusses what drove ralinepag's reduction in PAH clinical worsening in ADVANCE Outcomes and where the it could fit if approved.
Jean Elwing, MD, discusses a CHEST 2026 subgroup analysis showing ralinepag reduces clinical worsening in PAH even among patients with low-risk criteria.
Advertisement
Advertisement
Trending on HCPLive
1
Ralinepag's Benefit Spans Broad PAH Population, With Jean Elwing, MD
2
Sibeprenlimab Stabilizes eGFR Over 24 Months in IgA Nephropathy: VISIONARY
3
Retatrutide Lowers Albuminuria, Glomerular Pressure in Obesity and CKD
4
Ralinepag Cuts PAH Worsening in Low-Risk Patients, With Jean Elwing, MD
5